Stock Taper 
VRXA
$1.46
▼ DOWN 0.68% (-0.01)
KEY STATISTICS
Market Cap$206.46 M
52w High$27.36
52w Low$1.27
Dividend Yield—
Frequency—
P/E-2.52
Volume16.38K
Shares Out.141.41M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Christoph Antz
ABOUT
SECTOR
Healthcare
WENT PUBLIC
June 9, 2026
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
8
PRICE
$1.46 ▼ DOWN 0.68% (−$0.01)About Veraxa Biotech Holding AG
https://www.veraxa.com ↗Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed through a merger, developing next-generation cancer therapies like antibody-drug conjugates and bispecific T-cell engagers.
INDUSTRY
Biotechnology
A SERVICE VERAXA BIOTECH HOLDING AG IS KNOWN FOR
BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) Platform
Veraxa's proprietary platform enables the development of next-generation antibody-based cancer therapies, such as TCEs and ADCs, focusing on precise targeting to enhance safety and efficacy in their pipeline.
ETFS HOLDING THIS STOCK
ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
